Results 41 to 50 of about 1,723 (128)

Cross-sectional study on attitudes among general practitioners towards pneumococcal vaccination for middle-aged and elderly population in Hong Kong. [PDF]

PLoS ONE, 2013
OBJECTIVE: To study the attitudes among general practitioners towards pneumococcal vaccination for middle-aged (50-64) and elderly population (over 65) in Hong Kong and the factors affecting their decision to advise pneumococcal vaccination for those age
Lancelot W H Mui, Alvin Y S Chan, Albert Lee, John Lee   +3 more
doaj   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, Volume 13, Issue 35, 24 June 2026.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

A rare complication of a pneumococcal pneumonia [PDF]

Netherlands Heart Journal, 2009
In this case report we describe the development of a pyopneumopericarditis secondary to pneumonia, a complication that is rarely seen nowadays. (Neth Heart J 2009;17:393-5.).
M J, van Apeldoorn, E, Ozdas, F, Nijland, J M, Schroeder-Tanka   +3 more
openaire   +2 more sources

Extracellular Vesicles as Drivers of Lung Endothelial Dysfunction in ARDS: Mechanisms and Therapeutic Opportunities

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
This review summarizes how extracellular vesicles from diverse pulmonary and extrapulmonary sources contribute to endothelial dysfunction in ARDS and evaluates emerging endothelial‐targeted therapies for their potential to mitigate EV‐mediated pathogenic mechanisms.
Mohammed Yaman Al Matni, Patrick Belvitch, Steven M. Dudek, Eleftheria Letsiou   +3 more
wiley   +1 more source

Mast Cells in Acute COVID‐19 Patients

Allergy, EarlyView.
Ilan Zaffran, Hadas Pahima, Eli Ben‐Chetrit, Amir Jarjoui, Ilaria Puxeddu, Carl Zinner, Joana Vitte, Alexandar Tzankov, Francesca Levi‐Schaffer   +8 more
wiley   +1 more source

Burden of Severe Pneumonia, Pneumococcal Pneumonia and Pneumonia Deaths in Indian States: Modelling Based Estimates.

PLoS ONE, 2015
The burden of severe pneumonia in terms of morbidity and mortality is unknown in India especially at sub-national level. In this context, we aimed to estimate the number of severe pneumonia episodes, pneumococcal pneumonia episodes and pneumonia deaths ...
Habib Farooqui, Mark Jit, David L Heymann, Sanjay Zodpey   +3 more
doaj   +1 more source

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia

Molecular Medicine, 2019
Background Streptococcus pneumoniae is a major causative agent in community-acquired pneumonia and sepsis. Overwhelming lung inflammation during pneumococcal pneumonia may hamper lung function.
Alexander P. de Porto, Zhe Liu, Regina de Beer, Sandrine Florquin, Onno J. de Boer, Rudi W. Hendriks, Tom van der Poll, Alex F. de Vos   +7 more
doaj   +1 more source

Development of a Clinical Severity Score for Indian Sickle Cell Anaemia Patients

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Sickle cell anaemia (SCA) is a monogenic disorder but shows variable disease severity. We evaluated the utility of paediatric severity scores (PSS) in Indian patients and developed two modified scores: Indian Severity Score 1 (ISS1) by adding four clinical parameters to PSS, and ISS2 by excluding four biochemical measures from ISS1.
Suraj S. Nongmaithem, Amitabh Biswas, Swaroop Iyer, Jandhayala Vyshnavi, Archana Wath, Giriraj R. Chandak, Dipty Jain   +6 more
wiley   +1 more source

Thrombotic Events in Patients With Paroxysmal Nocturnal Haemoglobinuria Using Eculizumab: A Post‐Marketing Surveillance Sub‐Analysis

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Thrombotic events (TEs) account for approximately 40%–67% of deaths in untreated paroxysmal nocturnal haemoglobinuria (PNH). C5 inhibitor treatment (e.g., eculizumab and ravulizumab) greatly reduces the incidence of TEs in patients with PNH, but data on the characteristics of PNH patients experiencing TEs are limited.
Takayuki Ikezoe, Tatsuya Kawaguchi, Hideo Hayashi, Akihiko Shimono, Jun‐ichi Nishimura   +4 more
wiley   +1 more source

Single‐Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT‐035 Study

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Janus kinase inhibitors (JAKis), the current standard of care for myelofibrosis (MF), provide clinical benefit, but responses are frequently incomplete, non‐durable, and associated with cytopenias, underscoring the need for therapies with novel mechanisms of action.
Sebastian Grosicki, Habte Yimer, Rosa Ayala, Suning Chen, Hong Liu, Françoise Boyer, Paola Guglielmelli, Marco Brociner, Paolo Sportoletti, Gabor Mikala, Panagiotis Tsirigotis, Jin Zhang, Tomer Mark, Yi Chai, Andrea Ellero, Alessandro Lucchesi   +15 more
wiley   +1 more source